Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.
来源：PubMed发布日期：2026-04-01作者：Rothrock J, Najib U, Ailani J, Ashina S, Bao J0 次点击